Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes
NCT02344186 on ClinicalTrials.gov · last registry update 2022-07-29
A small phase 4 — 12 participants, against a typical 75. Its estimated completion date, 31 December 2022, has passed with no update to the record. Primary outcome, as filed: Changes in unfolded protein response markers. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Temple University
- Sponsor type
- Other
- Enrollment
- 12
- Started
- 2014-05
- Primary completion
- 2022-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Changes in unfolded protein response markers
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.